Publications by authors named "Virginia Bluthgen"
Article Synopsis
- The CheckMate-743 trial showed that nivolumab plus ipilimumab improves overall survival in patients with unresectable pleural mesothelioma compared to chemotherapy, but lacked representation of Latin American patients.
- A retrospective study evaluated this treatment's effectiveness and safety in 96 LATAM patients, focusing on their demographic and clinical characteristics, with a median follow-up of 24.1 months.
- Results indicated median progression-free survival of 8 months and overall survival of 22 months, confirming treatment benefits similar to other findings, with manageable adverse events reported.
Introduction: The LIPI, based on pretreatment derived neutrophils/[leukocytes-neutrophils] ratio (dNLR) and LDH, is associated with immune checkpoint inhibitors (ICI) outcomes in advanced non-small-cell lung cancer (NSCLC). We aimed to assess baseline LIPI correlation with durvalumab consolidation outcomes in the locally advanced setting.
Material And Methods: Multicentre retrospective study (330 patients) with stage III unresectable NSCLC treated with durvalumab after chemo-radiotherapy between April 2015 and December 2020; 65 patients treated with chemo-radiotherapy only.
Introduction: Durvalumab is the standard-of-care as consolidation therapy after chemo-radiotherapy in stage III unresectable non-small cell lung cancer (NSCLC); however, its activity across patients with NSCLC harbouring driver genomic alterations (dGA) is poorly characterised.
Material And Methods: Multicentre retrospective study including patients with stage III unresectable NSCLC treated with durvalumab after chemo-radiotherapy between April 2015 and October 2020 at 26 centres in Europe and America. Clinical and biological data were collected; dGA included: EGFR/BRAF/KRAS mutations (m) and ALK/ROS1 rearrangements (r).
Background: The established role of morphological evaluation of tumour-infiltrating lymphocytes (TILs) with immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) is unknown. We aimed to determine TIL association with the outcome for ICIs and for chemotherapy in advanced NSCLC.
Methods: This is a multicenter retrospective study of a nivolumab cohort of 221 patients treated between November 2012 and February 2017 and a chemotherapy cohort of 189 patients treated between June 2009 and October 2016.
Introduction: Quantitative assessment of heterogeneity by histogram analysis (HA) of tumor images can potentially provide a non-invasive prognostic biomarker. We assessed the prognostic value of HA and evaluated a correlation with molecular signature.
Results: CT scans performed between July 2009 and January 2015 from 692 patients were reviewed.